Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin
- PMID: 16446514
Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin
Abstract
Background: The best anticoagulation strategy for patients undergoing percutaneous coronary intervention (PCI) remains controversial. The primary objective of this study was to assess the feasibility of immediate sheath removal post-PCI in patients given a single low-dose intravenous (IV) bolus of enoxaparin as the sole anticoagulant.
Methods: In 53 patients with stable coronary disease undergoing elective PCI, a single IV bolus of 0.5 mg per kg enoxaparin was administered 10 minutes before PCI. Patients were pretreated with aspirin 100 mg and clopidogrel 300 mg. The femoral access sheaths were removed immediately after PCI by manual compression. Major and minor bleeding and coronary thrombosis were recorded. Anti-Xa levels were measured before, during and after PCI.
Results: One patient had an intracoronary thrombus 60 minutes after enoxaparin administration, and there was 1 ischemic stroke. Fifty-one of the 53 patients had their sheaths successfully pulled immediately post-PCI. One patient had a pseudoaneurysm requiring surgical repair, and 1 patient had a minor bleed. Postprocedural elevation of CK-MB > 3 times the upper limit of normal occurred in 7 patients (13.2%). Anti-Xa activity was 0.56 +/- 0.16 at 10 minutes post-IV injection, and then progressively decreased to 0.14 +/- 0.09 IU/ml at 6 hours after injection. Ten minutes after IV enoxaparin, 12 patients (23.5%) had anti-Xa levels < 0.5 IU/ml.
Conclusions: Immediate removal of femoral sheaths, after a single low-dose of IV enoxaparin for elective stenting appears feasible. However, a sizeable proportion of patients achieved anti-Xa levels below the widely agreed upon "therapeutic" level after injection.
Similar articles
-
A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.Chin Med J (Engl). 2006 Mar 5;119(5):355-9. Chin Med J (Engl). 2006. PMID: 16542576 Clinical Trial.
-
Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.J Invasive Cardiol. 2002 Aug;14(8):439-42. J Invasive Cardiol. 2002. PMID: 12147872
-
Six hour ambulation after elective coronary angioplasty and stenting with 7F guiding catheters ald low dose heparin.Kardiol Pol. 2003 Feb;58(2):93-7. Kardiol Pol. 2003. PMID: 14504634
-
Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention.J Invasive Cardiol. 2008 Sep;20(9):482-9. J Invasive Cardiol. 2008. PMID: 18762681 Review.
-
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Clin Ther. 2008. PMID: 19281914 Review.
Cited by
-
The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study).J Thromb Thrombolysis. 2009 Aug;28(2):224-8. doi: 10.1007/s11239-009-0326-2. Epub 2009 Mar 17. J Thromb Thrombolysis. 2009. PMID: 19291367 Clinical Trial.
-
Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs.J Thromb Thrombolysis. 2009 Oct;28(3):366-80. doi: 10.1007/s11239-009-0375-6. J Thromb Thrombolysis. 2009. PMID: 19597766 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous